Point72 Hong Kong LTD Arrowhead Pharmaceuticals, Inc. Transaction History

Point72 Hong Kong LTD

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$29.63 - $48.31 $306,433 - $499,622	10,342 Added 3242.01%	10,661 $352,000
Q2 2022 Aug 15, 2022	SELL	$27.79 - $50.61 $56,024 - $102,029	-2,016 Reduced 86.34%	319 $11,000
Q1 2022 May 16, 2022	BUY	$39.62 - $69.97 $92,512 - $163,379	2,335 New	2,335 $107,000
Q2 2021 Aug 16, 2021	SELL	$62.15 - $90.32 $42,448 - $61,688	-683 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$61.35 - $90.47 $21,779 - $32,116	355 Added 108.23%	683 $45,000
Q4 2020 Feb 16, 2021	BUY	$43.82 - $85.37 $14,372 - $28,001	328 New	328 $25,000
Q1 2020 May 15, 2020	SELL	$20.56 - $63.12 $2,302 - $7,069	-112 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$28.14 - $73.01 $3,151 - $8,177	112 New	112 $7,000
Q3 2019 Nov 14, 2019	SELL	$26.26 - $34.86 $236 - $313	-9 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$17.43 - $28.82 $644 - $1,066	-37 Reduced 80.43%	9 $0
Q1 2019 May 15, 2019	SELL	$12.05 - $20.18 $24 - $40	-2 Reduced 4.17%	46 $1,000
Q4 2018 Feb 14, 2019	BUY	$10.74 - $19.7 $515 - $945	48 New	48 $1,000

304

96.2M

388K

420K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.11B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.